Thromboelastography measurements of whole blood from factor VIII-deficient mice supplemented with rFVIII

Haemophilia

Volumn 11, Issue 4, 2005, Pages 346-352

  Landskroner, Kyle A ^a,b   Olson, N C ^b   Jesmok, G J ^a  

^a BAYER CORPORATION   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Haemophilia; Mouse; Rotational thromboelastography; Thrombin generation; Thromboelastogram

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; MUTANT PROTEIN; RECOMBINANT BLOOD CLOTTING FACTOR 8;

AMPLITUDE MODULATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TEST; COMPUTER PROGRAM; CONTROLLED STUDY; DOSE RESPONSE; FEASIBILITY STUDY; FIBRIN FORMATION; HEMOPHILIA A; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; THROMBIN TIME; THROMBOCYTE FUNCTION; THROMBOCYTE POOR PLASMA; THROMBOELASTOGRAPHY;

ANIMALS; BLOOD PLATELETS; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR VIII; HEMOPHILIA A; MICE; MICE, KNOCKOUT; THROMBELASTOGRAPHY; THROMBIN; TIME FACTORS;

EID: 22744458031     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2005.01104.x     Document Type: Article

References (23)

1. Kane W, Davie E. Blood coagulation factors V and VIII: structural similarities and their relationships to hemorrhagic and thrombotic disorders. Blood 1988; 71: 539-55.
2. Schroeder V, Chatterjee T, Kohler HP. Influence of blood coagulation factor XIII and FXIII Val34Leu on plasma clot formation measured by thromboelastography. Thromb Res 2001; 104: 467-74.
3. Fries D, Innerhofer P, Streif W et al. Coagulation monitoring and management of anticoagulation during cardiac assist device support. Ann Thorac Surg 2003; 76: 1593-7.
4. Sorensen B, Ingerslev J. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost 2004; 2: 102-10.
5. Sorensen B, Ingerslev J. Thromboelastography and recombinant factor VIIa - hemophilia and beyond. Semin Hematol 2004; 41: 140-4.
6. Sorensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thromboelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 2003; 1: 551-8.
7. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazazian HH Jr. Targeted disruption of the mouse factor VIII gene produced a model of haemophilia A. Nat Genet 1995; 10: 119-21.
8. Lang T, Toller W, Gutl M et al. Different effects of abciximab and cytochalasin D on clot strength in thromboelastography. J Thromb Haemost 2004; 2: 147-53.
9. Ingerslev J, Christiansen K, Calatzis A, Holm M, Sabroe Ebbesen L. Management and monitoring of recombinant activated factor VII. Blood Coagul Fibrinolysis 2000; 11 (Suppl. 1): S25-30.
10. Chandler W. The thromboelastography and the thromboelastograph technique. Semin Thromb Hemost 1995; 21: 1-6.
11. Mikaelsson M, Oswaldsson U, Jankowski MA. Measurement of factor VIII activity of B-domain deleted recombinant factor VIII. Semin Hematol 2001; 38: 13-23.
12. Butenas S, van't Veer C, Cawthern K, Brummel KE, Mann KG. Models of blood coagulation. Blood Coagul Fibrinolysis 2000; 11 (Suppl. 1): S9-13.
13. Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002; 100: 148-52.
14. van Dieijen G, Tans G, Rosing J, Hemker HC. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem 1981; 256: 3433-42.
15. Colman RHJ, Marder VJ, Clowes A, George JN. Overview of Hemostasis. Philadelphia, USA: Lippincott Williams & Wilkins, 2001; 3-16.
16. Gilbert GE, Sims PJ, Wiedmer T, Furie B, Furie BC, Shattil SJ. Platelet-derived microparticles express high affinity receptors for factor VIII. J Biol Chem 1991; 266: 17261-8.
17. Nesheim ME, Pittman DD, Wang JH, Slonosky D, Giles AR, Kaufman RJ. The binding of 35S-labeled recombinant factor VIII to activated and unactivated human platelets. J Biol Chem 1988; 263: 16467-70.
18. Brummel KE, Butenas S, Mann KG. An integrated study of fibrinogen during blood coagulation. J Biol Chem 1999; 274: 22862-70.
19. Allen GA, Wolberg AS, Oliver JA, Hoffman M, Roberts HR, Monroe DM. Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. J Thromb Haemost 2004; 2: 402-13.
20. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995; 10: 119-21.
21. Bi L, Sarkar R, Naas T et al. Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood 1996; 88: 3446-50.
22. Elder B, Lakich D, Gitschier J. Sequence of the murine factor VIII cDNA. Genomics 1993; 16: 374-9.
23. Landskroner K, Olson N, Jesmok G. Enhanced factor VIII activity measurements using ROTEG and factor VIII-/- mice whole blood. J Thromb Haemost 2004; 12: 2274-5.